Genetic Construct with MicroRNA Detector for T-ALL Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, particularly for T-cell acute lymphoblastic leukemia (T-ALL), face challenges in specificity and toxicity due to the targeting of cancer drivers that are also essential in normal tissues, leading to poor response rates and high toxicity in existing treatments.
Innovation Solution
A recombinant genetic construct is developed that utilizes T-ALL-specific microRNA profiles to differentiate between healthy and cancerous cells, regulating the expression of therapeutic genes only in T-ALL cells through a microRNA 'detector system' that includes a first promoter linked to a therapeutically active molecule and a second promoter linked to an inhibitor, ensuring targeted cell death without affecting healthy cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific cytotoxic drugs are used to treat cancer, then cancer cells are killed, but normal cells are also damaged causing high toxicity
Solution Approach 1:
The patent applies local quality by making the therapeutic gene expression cell-type specific through microRNA target sites. The first nucleic acid sequence contains microRNA target sites that are recognized by T-ALL specific microRNAs, enabling the therapeutic gene to be expressed only in T-ALL cells and not in normal cells, thus achieving localized treatment effect while sparing healthy tissues
Solution Approach 2:
The patent uses microRNA recognition as an intermediary mechanism to control gene expression. The microRNA target sites act as intermediaries that allow T-ALL specific microRNAs to bind and regulate the expression of the therapeutic gene, creating a specific signaling pathway that distinguishes cancer cells from normal cells and enables selective treatment
2Measurement precision
If target-specific agents are developed to address cancer drivers, then treatment precision is improved, but the complexity of the therapeutic system increases
Solution Approach 1:
The patent applies universality by designing a genetic construct that performs multiple functions within a single system. The construct simultaneously provides diagnostic functionality through microRNA target site recognition and therapeutic functionality through expression of the therapeutically active molecule, eliminating the need for separate diagnostic and therapeutic systems
Solution Approach 2:
The patent merges diagnostic and therapeutic functions into a single genetic construct. The first nucleic acid sequence containing microRNA target sites serves both as a diagnostic marker for T-ALL detection and as a regulatory element for therapeutic gene expression, combining what would traditionally be separate functions into one integrated system
3Productivity
If existing therapies are used for T-ALL, then some cancer cells are treated, but response rates remain low due to poor prognosis factors
Solution Approach 1:
The patent applies preliminary action by pre-equipping T-ALL cells with the genetic construct that contains both the microRNA target sites for detection and the therapeutic gene for treatment. This preliminary establishment of the therapeutic system within the cells ensures that when activated, the treatment can immediately take effect, improving response rates even in resistant or relapsed cases
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for high specificity and efficiency in delivering therapeutic molecules to T-ALL cells, reducing toxicity and improving treatment outcomes by ensuring that only cancerous cells are targeted, thereby enhancing the efficacy and safety of cancer therapy.
Implementation Method 1
MicroRNAs regulate gene expression post-transcriptionally by binding to complementary sequences usually located in 3′ UTR of their target mRNAs
Implementation Method 2
The genetic construct is capable of firstly using the microRNA profile to identify cancerous or tumourous T-ALL cells in a patient and distinguish the leukaemia cells from the patient's normal, healthy cells
Implementation Method 3
Addition of artificial sequences recognized by a specific microRNA to a transgene will induce its post-transcriptional silencing
Data Source
AI summary
The invention relates to genetic constructs comprising at least one microRNA target site, and vectors comprising such constructs. The genetic constructs and vectors can be used in diagnosis and therapy of a range of disorders, including cancers, for example T-cell acute lymphoblastic leukaemia (T-ALL).